If approved for the treatment of obesity, orforglipron could provide a convenient alternative for the millions of individuals living with obesity around the globe to continue their long-term health journey, said Kenneth Custer, executive vice president at Eli Lilly and president of Lilly Cardiometabolic Health, in a statement from the company
This news release was published by the Food and Drug Administration/National Institutes of Health on March 5, 2024.
Mounjaro (tirzepatide) a once-weekly injection that has shown significant benefits for weight loss and may be prescribed for obesity management depending on clinical suitability
Discussion Although DABP is becoming more prevalent, as the number of implicated medications grows, it is important to note that the presentation of DABP may differ from classic BP upon physical examination
HbA 1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression
The thyroid is a small, butterfly-shaped gland in the front of your neck
